

US010105492B2

(12) United States Patent

Simpson et al.

(54) MEDICAL CONNECTOR WITH INTERNAL VALVE MEMBER MOVABLE WITHIN MALE LUER PROJECTION

- (71) Applicant: ICU Medical, Inc., San Clemente, CA (US)
- (72) Inventors: Philip J. Simpson, Escondido, CA
 (US); Walter D. Gillespie, San Diego, CA (US); David G. Matsuura, Encinitas, CA (US)
- (73) Assignee: **ICU Medical, Inc.**, San Clemente, CA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 15/916,778
- (22) Filed: Mar. 9, 2018

(65) **Prior Publication Data**

US 2018/0193566 A1 Jul. 12, 2018

Related U.S. Application Data

- (63) Continuation of application No. 15/648,147, filed on Jul. 12, 2017, now Pat. No. 9,913,945, which is a (Continued)
- (51) Int. Cl. *A61M 5/31* (2006.01) *A61M 39/26* (2006.01)

		(Continued)	
TIO	C 1		

(Continued)

(10) Patent No.: US 10,105,492 B2

(45) **Date of Patent:** Oct. 23, 2018

(58) Field of Classification Search CPC A61M 39/10; A61M 39/22; A61M 39/26; A61M 2039/2473; A61M 2039/2486; (Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,254,997 A	9/1941	Fisher
2,456,045 A	12/1948	Brock
	(Con	tinued)

FOREIGN PATENT DOCUMENTS

CA	2747283 A1	7/2002
EP	0 158 030	10/1985
	(Cont	tinued)

OTHER PUBLICATIONS

U.S. Appl. No. 14/020,579, filed Oct. 22, 2015, Fangrow et al. (Continued)


Primary Examiner — Kami A Bosworth

(74) Attorney, Agent, or Firm — Knobbe, Martens, Olson & Bear, LLP

(57) **ABSTRACT**

Disclosed herein is a valve assembly comprising a male luer end portion and a female luer end portion and a passage for the transfer of fluids extending between the male and female luer end portions, valve means movable between a first position, in which the passage is closed, and a second position, in which the passage is open, biasing means for biasing the valve means toward the first position, and actuating means extending into the male luer end portion and coupled to the valve means to actuate the valve means when a female luer end portion of a medical accessory is engaged with the male luer end portion.

29 Claims, 15 Drawing Sheets



Related U.S. Application Data

continuation of application No. 14/052,592, filed on Oct. 11, 2013, now Pat. No. 9,707,346, which is a continuation of application No. 13/305,663, filed on Nov. 28, 2011, now Pat. No. 8,556,868, which is a continuation of application No. 12/789,255, filed on May 27, 2010, now Pat. No. 8,066,692, which is a continuation of application No. 10/584,920, filed as application No. PCT/US2004/042723 on Dec. 21, 2004, now Pat. No. 7,758,566.

- (60) Provisional application No. 60/532,916, filed on Dec. 30, 2003.
- (51) Int. Cl.

A61M 39/10	(2006.01)
A61M 39/22	(2006.01)
A61M 5/14	(2006.01)
A61M 5/168	(2006.01)
A61M 5/34	(2006.01)

(58) Field of Classification Search CPC A61M 2039/261; A61M 2039/262; A61M 2039/263; A61M 2039/267; A61M 2039/268; A61M 2005/3128

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,457,052	Α	12/1948	Le Clair
2,842,382	Α	7/1958	Franck
2,931,668	Α	4/1960	Baley
2,968,497	Α	1/1961	Treleman
3,127,892	Α	4/1964	Bellamy, Jr. et al.
3,304,047	Α	2/1967	Martin
3,334,860	Α	8/1967	Bolton, Jr.
3,538,950	Α	11/1970	Porteners
3,707,972	Α	1/1973	Villari et al.
3,729,031	Α	4/1973	Baldwin
3,986,508	Α	10/1976	Barrington
4,055,179	Α	10/1977	Manschot et al.
4,066,067	Α	1/1978	Micheli
4,076,285	Α	2/1978	Martinez
4,080,965	Α	3/1978	Phillips
4,084,606	Α	4/1978	Mittleman
4,121,585	Α	10/1978	Becker, Jr.
4,133,441	Α	1/1979	Mittleman et al.
4,143,853	Α	3/1979	Abramson
4,150,845	Α	4/1979	Kopacz et al.
4,195,632	Α	4/1980	Parker et al.
4,233,982	Α	11/1980	Bauer et al.
4,245,635	Α	1/1981	Kontos
4,324,239	Α	4/1982	Gordon et al.
4,334,551	Α	6/1982	Pfister
4,340,049	Α	7/1982	Munsch
4,379,458	Α	4/1983	Bauer et al.
4,387,879	Α	6/1983	Tauschinski
4,397,442	Α	8/1983	Larkin
4,430,073	Α	2/1984	Bemis et al.
4,436,125	Α	3/1984	Blenkush
4,457,749	Α	7/1984	Bellotti et al.
4,511,359	Α	4/1985	Vaillancourt
4,538,836	Α	9/1985	Kruetten
4,576,359	Α	3/1986	Oetiker
,- · · ,- - -			

4,610,469 A	9/1986	Wolff-Mooij
4,619,640 A	10/1986	Potolsky et al.
4,623,332 A	11/1986	Lindmayer et al.
4,629,159 A	12/1986	Wellenstam
4,660,803 A	4/1987	Johnston et al.
4,662,878 A	5/1987	Lindmayer
4,700,744 A	10/1987	Rutter et al.
4,723,603 A	2/1988	Plummer
4,728,075 A	3/1988	Paradis
4,745,950 A	5/1988	Mathieu
4,774,964 A	10/1988	Bonaldo De dei secondo et el
4,774,965 A 4.781.702 A	10/1988	Rodriguez et al. Herrli
4,781,702 A 4,804,015 A	11/1988 2/1989	Albinsson
4,816,024 A	3/1989	Sitar et al.
4,819,692 A	4/1989	Olson et al.
4,834,271 A	5/1989	Litwin
4,862,913 A	9/1989	Wildfang
4,863,201 A	9/1989	Carstens
4,883,483 A	11/1989	Lindmayer
4,915,687 A	4/1990	Sivert
4,917,669 A	4/1990	Bonaldo
4,935,010 A	6/1990	Cox et al.
4,949,745 A	8/1990	McKeon
4,950,260 A	8/1990	Bonaldo
D313,277 S	12/1990	Haining
D314,050 S	1/1991	Sone
5,006,114 A	4/1991	Rogers et al.
5,021,059 A 5,047.021 A	6/1991	Kensey et al.
5,047,021 A 5,065,783 A	9/1991 11/1991	Utterberg Ogle, II
5,070,885 A	12/1991	Bonaldo
5,098,385 A	3/1992	Walsh
5,108,376 A	4/1992	Bonaldo
5,122,123 A	6/1992	Vaillancourt
5,139,483 A	8/1992	Ryan
5,147,333 A	9/1992	Raines
5,154,703 A	10/1992	Bonaldo
RE34,223 E	4/1993	Bonaldo
5,199,948 A	4/1993	McPhee
5,201,725 A	4/1993	Kling
5,203,775 A	4/1993	Frank et al.
5,211,634 A	5/1993	Vaillancourt
5,215,537 A	6/1993	Lynn et al.
5,215,538 A 5,242,393 A	6/1993 9/1993	Larkin Brimhall at al
5,242,425 A	9/1993	Brimhall et al. White et al.
5,251,873 A	10/1993	Atkinson et al.
5,269,771 A	12/1993	Thomas et al.
5,273,533 A	12/1993	Bonaldo
5,279,571 A	1/1994	Larkin
5,281,206 A	1/1994	Lopez
5,284,475 A	2/1994	Mackal
5,295,657 A	3/1994	Atkinson
5,301,686 A	4/1994	Newman
5,306,243 A	4/1994	Bonaldo
5,312,377 A	5/1994	Dalton
5,324,270 A	6/1994	Kayan et al.
5,330,450 A	7/1994	Lopez
5,334,159 A 5,344,414 A	8/1994	Turkel
5,344,414 A 5,360,413 A	9/1994 11/1994	Lopez et al.
5,370,636 A	12/1994	Leason et al. Von Witzleben
5,380,306 A	1/1995	Brinon
5,385,372 A	1/1995	Utterberg
5,390,898 A	2/1995	Smedley et al.
5,391,150 A	2/1995	Richmond
5,395,348 A	3/1995	Ryan
5,397,314 A	3/1995	Farley et al.
5,400,500 A	3/1995	Behnke et al.
5,401,245 A	3/1995	Haining
5,402,826 A	4/1995	Molnar et al.
5,402,982 A	4/1995	Atkinson et al.
5,405,323 A	4/1995	Rogers et al.
5,405,331 A	4/1995	Behnke et al.
5,405,333 A	4/1995	Richmond
5,411,499 A	5/1995	Dudar et al.
5,417,673 A	5/1995	Gordon
5,423,791 A	6/1995	Bartlett

(56) **References** Cited

U.S. PATENT DOCUMENTS

	0.5.	PATENT	DOCUMENTS
5,425,465	Α	6/1995	Healy
5,433,330	Α	7/1995	Yatsko et al.
5,439,451	A	8/1995	Collinson et al.
5,441,487 5,445,623	A A	8/1995 8/1995	Vedder Richmond
5,447,177	A	9/1995	Ricken et al.
5,456,668	Â	10/1995	Ogle, II
5,456,675	Α	10/1995	Wolbring et al.
5,462,255	A	10/1995	Rosen et al.
5,464,399	A	11/1995	Boettger
5,470,319 5,470,327	A A	11/1995 11/1995	Mayer Helgren et al.
5,474,536	Ā	12/1995	Bonaldo
5,480,393	Α	1/1996	Bommarito
5,489,274	A	2/1996	Chu et al.
5,492,147 5,501,426	A A	2/1996	Challender et al.
5,507,744	Ā	3/1996 4/1996	Atkinson et al. Tay et al.
5,514,177	Ā	5/1996	Kurz et al.
5,518,026	Α	5/1996	Benjey
5,520,665	A	5/1996	Fleetwood
5,520,666 5,527,284	A A	5/1996 6/1996	Choudhury et al. Ohnemus et al.
5,533,708	Ā	7/1996	Atkinson et al.
5,533,983	A	7/1996	Haining
5,533,996	A	7/1996	Murphey et al.
5,535,785	A	7/1996	Werge et al.
5,540,661 5,549,566	A A	7/1996 8/1996	Tomisaka et al. Elias et al.
5,549,577	Â	8/1996	Siegel et al.
5,549,651	Α	8/1996	Lynn
5,552,118	A	9/1996	Mayer
5,555,908 5,569,235	A A	9/1996 10/1996	Edwards et al. Ross et al.
5,573,516	A	11/1996	Tyner
5,575,769	A	11/1996	Vaillancourt
5,578,059	A	11/1996	Patzer
5,584,819	A	12/1996	Kopfer
5,591,137 5,591,143	A A	1/1997 1/1997	Stevens Trombley, III et al.
5,597,536	Ā	1/1997	Mayer
5,616,129	Α	4/1997	Mayer
5,616,130	A	4/1997	Mayer
RE35,539 5,643,224	E A	6/1997 7/1997	Bonaldo Szapiro et al.
5,645,538	Ā	7/1997	Richmond
5,674,206	A	10/1997	Allton et al.
5,676,346	A	10/1997	Leinsing
5,685,866	A	11/1997	Lopez
5,685,868 5,699,821	A A	11/1997 12/1997	Lundquist Paradis
5,700,248	A	12/1997	Lopez
5,702,374	Α	12/1997	Johnson
5,709,243	A	1/1998	Wells et al.
5,735,826 5,738,144	A A	4/1998 4/1998	Richmond Rogers
5,749,861	Ā	5/1998	Guala et al.
RE35,841	E	7/1998	Frank et al.
5,782,816	A	7/1998	Werschmidt et al.
5,785,693	A A	7/1998	Haining
5,806,831 5,814,024	A	9/1998 9/1998	Paradis Thompson et al.
5,820,601	Â	10/1998	Mayer
5,839,715	Α	11/1998	Leinsing
5,848,994	A	12/1998	Richmond
5,947,954 6,029,946	A A	9/1999 2/2000	Bonaldo Doyle
6,036,171	A	3/2000	Weinheimer et al.
6,039,302	A	3/2000	Cote, Sr. et al.
6,041,805	Α	3/2000	Gydesen et al.
6,050,978	A	4/2000	Orr et al.
6,063,062	A A	5/2000	Paradis Paradis
6,068,011 6,068,617	A A	5/2000 5/2000	Richmond
6,079,432	A	6/2000	Paradis
,,			

6,106,502 A	8/2000	Richmond
6,113,068 A	9/2000	Ryan
6,142,446 A	11/2000	Leinsing
6,152,913 A	11/2000	Feith et al.
6,168,137 B1	1/2001	Paradis
6,170,522 B1	1/2001	Tanida
6,171,287 B1	1/2001	Lynn et al.
6,189,859 B1	2/2001	Rohrbough et al.
6,206,860 B1	3/2001	Richmond
6,224,578 B1	5/2001	Davis et al.
6,242,393 B1	6/2001	Ishida et al.
6,245,048 B1	6/2001	Fangrow et al.
6,290,206 B1	9/2001	Doyle
6,299,132 B1	10/2001	Weinheimer et al.
6,325,100 B1	12/2001	Bunschoten et al.
6,402,207 B1	6/2002	Segal et al.
6,428,520 B1	8/2002	Lopez
6,431,219 B1	8/2002	Redler et al.
6,485,472 B1	11/2002	Richmond
6,499,719 B1	12/2002	Clancy et al.
6,508,792 B2	1/2003	Szames et al.
6,508,807 B1	1/2003	Peters
6,541,802 B2	4/2003	Doyle
6,543,745 B1	4/2003	Enerson
6,581,906 B2	6/2003	Pott et al.
6,585,229 B2	7/2003	Cote et al.
6,595,964 B2	7/2003	Finley et al.
6,595,981 B2	7/2003	Huet
6,609,696 B2	8/2003	Enerson
6,612,624 B1	9/2003	Segal et al.
6,666,852 B2	12/2003	Niedospial, Jr.
6,695,817 B1	2/2004	Fangrow
6,745,998 B2	6/2004	Doyle
6,808,161 B1	10/2004	Hishikawa
6,840,501 B2	1/2005	Doyle
6,869,426 B2	3/2005	Ganem
6,875,205 B2	4/2005	Leinsing
6,899,315 B2	5/2005	Mailville et al.
6,911,025 B2	6/2005	Miyahara
6,955,669 B2	10/2005	Curutcharry
6,964,406 B2	11/2005	Doyle
7,004,934 B2	2/2006	Vaillancourt
7,037,302 B2	5/2006	Vaillancourt
7,040,598 B2	5/2006	Raybuck
7,044,441 B2	5/2006	Doyle
7,100,891 B2	9/2006	Doyle
7,125,396 B2	10/2006	Leinsing et al.
7,137,654 B2	11/2006	Segal et al.
7,140,592 B2	11/2006	Phillips
7,160,272 B1	1/2007	Eyal et al.
7,182,313 B2	2/2007	Doyle
7,195,228 B2	3/2007	Tiberghien et al.
7,244,249 B2	7/2007	Leinsing et al.
7,306,197 B2	12/2007	Parrino et al.
7,306,198 B2	12/2007	Doyle
7,306,566 B2	12/2007	Raybuck
7,347,458 B2	3/2008	Rome et al.
7,350,764 B2	4/2008	Raybuck
7,361,164 B2	4/2008	Simpson et al.
7,497,484 B2	3/2009	Ziman
7,559,530 B2	7/2009	Korogi et al.
7,588,563 B2	9/2009	Guala
7,645,274 B2	1/2010	Whitley
7,651,481 B2	1/2010	Raybuck
7,666,170 B2	2/2010	Guala
7,758,566 B2	7/2010	Simpson et al.
7,766,304 B2	8/2010	Phillips
7,766,897 B2	8/2010	Ramsey et al.
7,803,139 B2	9/2010	Fangrow, Jr.
7,803,140 B2	9/2010	Fangrow, Jr.
7,815,614 B2	10/2010	Fangrow, Jr.
7,837,658 B2	11/2010	Cote et al.
7,857,805 B2	12/2010	Raines
7,976,532 B2	7/2011	Kitani et al.
7,998,134 B2	8/2011	Fangrow et al.
8,066,692 B2	11/2011	Simpson et al.
8,177,772 B2	5/2012	Christensen et al.
8,211,069 B2	7/2012	Fangrow, Jr.
8,225,826 B2	7/2012	
0,220,020 DZ	112012	Horppu et al.

(56)**References** Cited

U.S. PATENT DOCUMENTS

8,231,567			
	D 2	7/2012	Tonnican of al
	B2		Tennican et al.
8,262,628	B2	9/2012	Fangrow, Jr.
8,281,824	B2	10/2012	Molema et al.
8,286,936	B2	10/2012	Kitani et al.
8,287,513	B2	10/2012	Ellstrom et al.
8,454,579	B2	6/2013	Fangrow, Jr.
8,556,868	B2	10/2013	Simpson et al.
8,721,628	B2	5/2014	Ziman
8,777,908	B2	7/2014	Fangrow, Jr.
8 777 000	B2	7/2014	
8,777,909			Fangrow, Jr.
8,888,758	B2	11/2014	Mansour et al.
9,114,242	B2	8/2015	Fangrow et al.
9,126,028	B2	9/2015	Fangrow et al.
9,126,029	B2	9/2015	Fangrow et al.
9,168,366	B2	10/2015	Fangrow et al.
9,345,641	B2	5/2016	Kraus et al.
9,358,379	B2	6/2016	Fangrow
9,592,344	B2	3/2017	Simpson et al.
9,707,346	B2	7/2017	
			Simpson et al.
9,913,945	B2	3/2018	Simpson et al.
2002/0066715	A1	6/2002	Niedospial, Jr.
2003/0066978	A1	4/2003	Enerson
2003/0136932	A1	7/2003	Doyle
2003/0208165	A1	11/2003	Christensen et al.
2004/0074541	A1	4/2004	Sharpe
			Kiehne
2004/0124388	A1	7/2004	
2004/0124389	A1	7/2004	Phillips
2004/0244848	A1	12/2004	Maldavs
2005/0015075	A1	1/2005	Wright et al.
2005/0124942	A1	6/2005	Richmond
2005/0228362	A1	10/2005	Vaillancourt
2006/0025751	A1	2/2006	Roy et al.
2006/0058734	A1	3/2006	Phillips
2006/0065873	A1	3/2006	Doyle
2006/0129109	A1	6/2006	Shaw et al.
2006/0142730	A1	6/2006	Proulx et al.
2006/0142735	A1	6/2006	Whitley
2006/0149213	A1	7/2006	Raybuck
2006/0157984	A1	7/2006	Rome et al.
2006/0161115	A1	7/2006	
			Fangrow
2006/0202146	A1	9/2006	Doyle
2000/0202110	A1	11/2000	Nordgren
2006/0253084		11/2006	
	Al	2/2007	Guala
2006/0253084 2007/0043334	A1	2/2007	Guala
2006/0253084 2007/0043334 2007/0088292	A1 A1	2/2007 4/2007	Guala Fangrow
2006/0253084 2007/0043334 2007/0088292 2007/0088293	A1 A1 A1	2/2007 4/2007 4/2007	Guala
2006/0253084 2007/0043334 2007/0088292	A1 A1	2/2007 4/2007	Guala Fangrow Fangrow
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294	A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007	Guala Fangrow Fangrow Fangrow
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327	A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 4/2007	Guala Fangrow Fangrow Guala
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294	A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007	Guala Fangrow Fangrow Fangrow
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0102923	A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 4/2007 5/2007	Guala Fangrow Fangrow Fangrow Guala Niemela
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0102923 2007/0102923	A1 A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 4/2007 5/2007 8/2007	Guala Fangrow Fangrow Guala Niemela Lim et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088294 2007/0088294 2007/0088327 2007/0102923 2007/0102923 2007/0179453 2008/0103485	A1 A1 A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0102923 2007/0102923	A1 A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 4/2007 5/2007 8/2007	Guala Fangrow Fangrow Guala Niemela Lim et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0102923 2007/0102923 2007/0179453 2008/0103485 2008/0190485	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0102923 2007/0179453 2008/0190485 2008/0190485	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0102923 2007/0179453 2008/0103485 2008/0190455 2008/0290657 2009/0177170	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0102923 2007/0179453 2008/0103485 2008/0190455 2008/0290657 2009/0177170	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088294 2007/0088294 2007/0102923 2007/0179453 2008/0103485 2008/0190485 2008/0290657 2009/0177170 2010/0063482	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 5/2008 8/2008 8/2008 11/2008 7/2009 3/2010	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0102923 2007/0179453 2008/0103485 2008/0190485 2008/0290657 2009/0177170 2010/0063482 2010/0174242	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 5/2008 8/2008 8/2008 11/2008 7/2009 3/2010 7/2010	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088294 2007/0088294 2007/0102923 2007/0179453 2008/0103485 2008/0190485 2008/0290657 2009/0177170 2010/0063482	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 5/2008 8/2008 8/2008 11/2008 7/2009 3/2010	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088293 2007/0108293 2007/0102923 2007/0102923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0102923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0253070 2011/0062703	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 5/2008 8/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088293 2007/0108293 2007/0102923 2007/0102923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/012923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/036931	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al. Lopez Kamen et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/0102923 2007/0102923 2008/0103485 2008/0190485 2008/0190485 2008/0290657 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/0306931 2012/0031515	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2008 8/2008 8/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0102923 2007/0102923 2007/0179453 2008/0103485 2008/0103485 2008/0170174 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/036931 2012/0031515 2012/0039101	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2008 8/2008 8/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker Carlyon et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/0102923 2007/0102923 2008/0103485 2008/0190485 2008/0190485 2008/0290657 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/0306931 2012/0031515	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2008 8/2008 8/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/036931 2012/0389101 2012/0316536	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2012 4/2012 12/2012	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088327 2007/0102923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0253070 2011/0062703 2011/036931 2012/031515 2012/0089101 2012/0316536 2013/0035668	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 3/2010 3/2011 12/2011 2/2012 4/2012 12/2012 2/2013	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al. Kitani et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/012923 2008/0102923 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/036931 2012/031515 2012/0031515 2012/0035668 2013/0335668 2013/0335668	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 12/2012 2/2013 11/2013	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/012923 2008/0102923 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/036931 2012/031515 2012/0031515 2012/0035668 2013/0335668 2013/0335668	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 12/2012 2/2013 11/2013	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al. Ritani et al. Reichart et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/012923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/063482 2010/0174242 2010/0253070 2011/0662703 2011/036931 2012/0031515 2012/0031515 2012/0031515 2012/0035668 2013/0317483 2014/0246616	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 8/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 12/2012 12/2013 9/2014	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al. Kitani et al. Reichart et al. Fangrow
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/012923 2008/0102923 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/036931 2012/031515 2012/0031515 2012/0035668 2013/0335668 2013/0335668	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 12/2012 2/2013 11/2013	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al. Ritani et al. Reichart et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/012923 2007/0179453 2008/019485 2008/019485 2008/0290657 2009/0177170 2010/0063482 2010/0174242 2010/025307 2011/0062703 2011/0306931 2012/031515 2012/0089101 2012/031515 2013/0317483 2014/0246616 2015/0051555	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 12/2012 12/2013 9/2014 2/2015	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al. Lopez Kamen et al. Whitaker Carlyon et al. Carlyon et al. Carrez et al. Kitani et al. Fangrow Fangrow, Jr.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088293 2007/0102923 2007/0102923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2010/006370 2011/0062703 2011/0062703 2011/0062703 2011/00631515 2012/0089101 2012/0316536 2013/035668 2013/035668 2013/035655 2015/0258324	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 8/2008 7/2009 3/2010 7/2010 10/2010 3/2011 2/2012 4/2012 2/2013 11/2013 9/2014 2/2015 9/2015	Guala Fangrow Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al. Kitani et al. Reichart et al. Fangrow Fangrow, Jr. Chida et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063485 2011/0063703 2011/0062703 2011/0062703 2011/006315 2012/0089101 2012/0316536 2013/035668 2013/0317483 2014/024616 2015/051555 2015/0258324 2016/0213910	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 12/2012 12/2013 9/2014 2/2015	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al. Lopez Kamen et al. Whitaker Carlyon et al. Carlyon et al. Carrez et al. Kitani et al. Fangrow Fangrow, Jr.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063485 2011/0063703 2011/0062703 2011/0062703 2011/006315 2012/0089101 2012/0316536 2013/035668 2013/0317483 2014/024616 2015/051555 2015/0258324 2016/0213910	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 8/2007 5/2008 7/2009 3/2010 7/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 12/2012 1/2013 9/2014 9/2015 7/2016	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al. Kitani et al. Reichart et al. Fangrow, Jr. Chida et al. Fangrow, Jr. et al
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0253070 2011/0062703 2011/0062703 2011/0062703 2011/0062703 2011/0062703 2011/0062703 2011/005482 2013/031546 2013/0315468 2013/0315483 2014/0246616 2015/0051555 2015/0258324 2016/0213910 2016/0263367	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 8/2007 5/2008 7/2009 3/2010 7/2010 3/2010 7/2010 3/2011 12/2011 2/2012 4/2012 2/2013 11/2013 9/2014 2/2015 7/2016 9/2016	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al. Kitani et al. Reichart et al. Fangrow, Jr. Chida et al. Fangrow, Jr. et al Fangrow et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/0102923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/0062703 2011/0062703 2011/0062703 2011/0063463 2013/0315155 2012/003151656 2013/0315468 2013/0315468 2013/0317483 2014/0246616 2015/0258324 2016/0213910 2016/0263367 2017/0296801	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 2/2013 11/2013 9/2014 2/2015 9/2016 9/2016 10/2017	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al. Lopez Kamen et al. Whitaker Carlyon et al. Reichart et al. Fangrow Fangrow, Jr. Chida et al. Fangrow, Jr. Et al. Fangrow, Jr.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0253070 2011/0062703 2011/0062703 2011/0062703 2011/0062703 2011/0062703 2011/0062703 2011/005482 2013/031546 2013/0315468 2013/0315483 2014/0246616 2015/0051555 2015/0258324 2016/0213910 2016/0263367	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 5/2007 8/2007 5/2008 7/2009 3/2010 7/2010 3/2010 7/2010 3/2011 12/2011 2/2012 4/2012 2/2013 11/2013 9/2014 2/2015 7/2016 9/2016	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Lopez Kamen et al. Whitaker Carlyon et al. Carrez et al. Kitani et al. Reichart et al. Fangrow, Jr. Chida et al. Fangrow, Jr. et al Fangrow et al.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/036931 2012/031515 2012/0031515 2012/0031515 2012/0035668 2013/0317483 2014/0246616 2015/0051555 2015/0258324 2016/0213910 2016/0263367 2017/0296801 2018/0015275	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 2/2013 11/2013 9/2014 2/2015 9/2016 10/2017 1/2018	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al. Carrez et al. Reichart et al. Fangrow, Jr. Chida et al. Fangrow, Jr. Chida et al. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr.
2006/0253084 2007/0043334 2007/0088292 2007/0088293 2007/0088294 2007/0088294 2007/012923 2007/0102923 2007/0179453 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2008/0190485 2009/0177170 2010/0063482 2010/0174242 2010/0253070 2011/0062703 2011/0062703 2011/0062703 2011/0062703 2011/0063463 2013/0315155 2012/003151656 2013/0315468 2013/0315468 2013/0317483 2014/0246616 2015/0258324 2016/0213910 2016/0263367 2017/0296801	A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A	2/2007 4/2007 4/2007 4/2007 5/2007 8/2007 5/2008 8/2008 11/2008 7/2009 3/2010 7/2010 10/2010 3/2011 12/2011 2/2012 4/2012 2/2013 11/2013 9/2014 2/2015 9/2016 9/2016 10/2017	Guala Fangrow Fangrow Guala Niemela Lim et al. Kruger Guala McKeon, III Kitani et al. Mansour et al. Anderson et al. Cheon et al. Lopez Kamen et al. Whitaker Carlyon et al. Reichart et al. Fangrow Fangrow, Jr. Chida et al. Fangrow, Jr. Et al. Fangrow, Jr.

FOREIGN PATENT DOCUMENTS

EP	0 368 473 A2	5/1990
EP	0 791 371	8/1997
EP	0 795 342	9/1997
EP	1 946 792	7/2008
GB	2 116 277	9/1983
GB	2 118 440	11/1983
GB	2 353 078	2/2001
JP	56-72659	6/1981
JP	58-13216	1/1983
JP	59-41429	3/1984
JP	60-89488	6/1985
JP	63-175383	11/1988
JP	11-311234	11/1999
JP	2001-187990 A	7/2001
JP	2004-000483 A	1/2004
WO	WO 1995/32748	12/1995
WO	WO 2001/03756	1/2001
WO	WO 2001/23026	4/2001
WO	WO 2002/096500	12/2002
WO	WO 2003/013646	2/2003
wõ	WO 2004/060474	7/2004
WO	WO 2004/082756	9/2004
WO	WO 2006/076656	7/2006
WŐ	WO 2006/088858	8/2006
WO	WO 2006/124756	11/2006
WÕ	WO 2007/008511	1/2007
WÕ	WO 2007/112944	10/2007
WO	WO 2008/144447	11/2008
WO	WO 2010/071848	6/2010
WŐ	WO 2011/139995	11/2011
WŐ	WO 2013/036854	3/2013
		2.3010

OTHER PUBLICATIONS

U.S. Appl. No. 15/499,740, filed Apr. 27, 2017, Fangrow. U.S. Appl. No. 15/789,242, filed Oct. 20, 2016, Fangrow, Jr. et al. Air Embolism and Exsanguination from Separation of Two-Piece Side Port/Hemostasis Valve Cardiac Catheter Introducers, ECRI Institute, Jan. 1995, in 2 pages, http://www.mdsr.ecri.org/summary/ detail.aspx?doc_id=8098.

Injection Site, Molded Products, Inc., Apr. 2, 2004, in 1 page, https://web.archive.org/web/20040402123354/https://www. moldedproducts.com/injectionsite.htm.

EPO Search Report re EP Application No. 08 755 612.2, dated Feb. 23, 2012 in 5 pages.

EPO Examination Report re EP Application No. 08 755 612.2, dated Nov. 20, 2013 in 5 pages.

EPO Examination Report re EP Application No. 08 755 612.2, dated Dec. 5, 2012 in 6 pages.

International Search Report for PCT/US2006/026124, dated Mar. 3, 2007 in 5 pgs.

International Written Opinion for PCT/US2006/026124, dated Jan. 10, 2008 in 11 pgs.

International Search Report and Written Opinion of International Application No. PCT/US2008/063797 dated Dec. 30, 2008 in 21 pages.

International Preliminary Report on Patentability, International Application No. PCT/US2008/063797 dated Nov. 17, 2009 in 11 pages. International Search Report and Written Opinion for International Application No. PCT/US2004/042723, dated Jun. 28, 2005 in 16 pages.

International Written Opinion of International Application No. PCT/US2004/042723 dated Jul. 3, 2006 in 10 pages.

ICU Medical, Inc. U.S. Appl. No. 11/417,648, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 11/417,671, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 11/417,882, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 11/417,909, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 11/417,923, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 15/789,242, filed Oct. 20, 2016.




FIG. 1







FIG. 2












FIG. 6




FIG. 7





FIG. 8








FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15

35

MEDICAL CONNECTOR WITH INTERNAL VALVE MEMBER MOVABLE WITHIN MALE LUER PROJECTION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/648,147, filed Jul. 12, 2017, now U.S. Pat. No. 9,913,945, which is a continuation of U.S. patent application Ser. No. 14/052,592, filed Oct. 11, 2013, now U.S. Pat. No. 9,707,346, which is a continuation of U.S. patent application Ser. No. 13/305,663, filed Nov. 28, 2011, now U.S. Pat. No. 8,556,868, which is a continuation of U.S. 15 patent application Ser. No. 12/789,255, filed May 27, 2010, now U.S. Pat. No. 8,066,692, which is a continuation of U.S. patent application Ser. No. 10/584,920, filed Dec. 28, 2006, now U.S. Pat. No. 7,758,566, which is the National Stage Entry of International Application No. PCT/US04/42723, 20 filed Dec. 21, 2004, which claims the benefit of U.S. Provisional Application No. 60/532,916, filed Dec. 30, 2003; the entire contents of all of which are hereby incorporated by reference herein and made a part of this specification. Any and all priority claims identified in the Appli-²⁵ cation Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to medical fluid delivery valves and more particularly to valve assemblies for use with syringes or other medical dispensing devices.

Description of the Related Art

Syringes are commonly used to deliver medications and other biological fluids to a patient. The syringe typically has 40 a plunger which is sealingly engaged with an outer cylindrical chamber to form an inner fluid-receiving chamber. A 'male' luer fitting is usually provided at a delivery end of the chamber which receives a female luer fitting with a needle assembly or the like. The fluid channel joining the cavity to 45 the luer fitting is usually open, so that when the needle is removed, the cavity is open to the environment. This is problematic since many medications and biological fluids are sensitive (or can degrade when exposed) to the environment. 50

It is therefore an object of the present invention to provide a novel valve assembly for use with a syringe or other medical dispensing devices, enabling the latter to be closed to the environment when in an unattached condition.

SUMMARY OF THE INVENTION

In one of its aspects, the present invention provides a valve assembly comprising a male luer end portion, a female luer end portion and a channel for the transfer of fluids 60 between the male and female luer end portions, valve means movable between a closed position and an open position, biasing means for biasing the valve means toward the closed position, and actuating means extending into the male luer end portion and coupled to the valve means to actuate the 65 valve means when a female luer end portion of a medical accessory is coupled with the male luer end portion.

In an embodiment the male luer end portion has an inner projection and outer threaded sheath which is spaced therefrom to receive the female luer end portion therebetween. The actuating means includes an actuating member positioned between the outer threaded sheath and the inner projection.

In an embodiment, the valve means includes a valve seat and a valve member moveable relative thereto. The channel includes a first channel portion adjacent the female luer end portion and the inner projection includes a second channel portion. The valve member has a valve channel portion in fluid communication with the first and second channel portions. The valve seat is formed in the second channel portion and the valve member is integrally formed with the female luer end portion.

In one embodiment, the valve member includes an anchor flange extending outwardly toward an inner surface of the housing portion. In this case, the housing portion is coupled to the male luer end portion for movement therewith relative to the valve member. The male luer end portion engages the anchor flange when the valve means is in the closed position and the male luer end portion is spaced from said anchor flange when the valve means is in the open position. The housing portion terminates at an end region adjacent the female luer end portion, the biasing means includes a compression spring located within the housing between the end region and the outer anchor flange.

In another of its aspects, the present invention provides a 30 medical dispensing device comprising a body having a chamber therein to contain a fluid material, a valve assembly in fluid communication with the chamber, the valve assembly having a male coupling member for engaging a female coupling member on a medical accessory to form a fluid coupling between the medical dispensing device and the medical accessory, the valve assembly further comprising flow control means operable to control fluid flow through the male coupling member, the flow control means being operable to be displaced by the female coupling member to open the male coupling member when female coupling member is operatively connected therewith, the flow control means being operable to be displaced by the female coupling member to close the male coupling member when the female coupling member is disconnected therefrom.

In one embodiment, the male coupling member includes an inner male portion and an outer sheath portion spaced therefrom to form a passage there between for receiving the female coupling member, the flow control means including at least one valve actuating portion positioned in the passage to abut the female coupling member and to displace the valve member during the travel of the female coupling member along the passage. The valve assembly includes a valve member and a valve seat, wherein the valve member is positioned against the seat to close the male coupling 55 member. The valve actuating portion includes a pair of abutment elements which are spaced from one another along the passage to receive the female coupling member there between, wherein the pair of abutment elements are operable to travel with the female coupling member along the passage.

In one embodiment, the actuating portion is longitudinally oriented relative to the passage and the abutment elements are positioned along the actuating portion.

The valve member includes a back plate and a plurality of actuating portions equally spaced on the back plate, each of the actuating portions having first and second abutment elements.

In one embodiment, the valve actuating portion includes a locking flange which is adjacent one of the abutment elements. The valve assembly includes a locking seat to receive the locking flange when the male coupling member is in the closed position. The actuating portion has a distal 5 end region, the locking flange being located adjacent the distal end region and the locking seat is formed in the outer sheath portion. The actuating portion is thus arranged to flex in order to displace the locking flange from the locking seat.

In yet another aspect, the present invention provides a 10 medical dispensing device comprising a body having a chamber therein to contain a fluid material, a valve assembly in fluid communication with the chamber, the valve assembly having a male coupling member for engaging a female coupling member on a medical accessory to form a fluid 15 coupling between the medical dispensing device and the medical accessory, the male coupling member including a projection and an outer valve member movable relative to the projection, the projection and the outer valve member forming a fluid channel there between, a sheath portion 20 provided a syringe assembly 10 comprising a syringe 12 and encircling the projection and spaced therefrom to form a passage to receive the female coupling member, the valve member being engageable with the female coupling member and movable relative to the projection to open the fluid channel when the female coupling member is connected 25 with the male coupling member.

In one embodiment, the valve member forms an outer surface of the male coupling portion.

In an embodiment, biasing means is provided to bias the valve member toward an engaged position with the projec- 30 tion to close the fluid channel. In this particular case, the passage ends at an inner wall and the biasing means includes a spring located between the inner wall and the valve member.

In one embodiment, the projection is fixed to the body and 35 includes an inner passage, the inner passage having one end which is open to the chamber and another end which is open to the fluid channel. The projection also includes an enlarged end portion, the valve member including an outer portion arranged to engage the enlarged end portion to close the fluid 40 channel. In this case the enlarged end portion and the outer end portion on the valve member have mating bevelled surfaces.

In one embodiment, the female coupling member has a leading segment, the valve member being dimensioned to fit 45 within the leading segment.

Preferably, the medical dispensing device includes such items as a syringe, an IV bottle, an IV line, a powder and/or atomized fluid and/or gas inhalant dispenser, an implant delivery dispenser, a ventilator, a syringe pump, an intuba- 50 tion tube, a gastrointestinal feeding tube or a plurality and/or a combination thereof.

Preferably, the medical material is in solid, liquid or gaseous form or a combination thereof and has beneficial properties to enhance life, to promote health, to cure and/or 55 treat a disease, condition or ailment, to monitor and/or indicate a bodily function or a combination thereof. For example, the medical material may be useful for, among others, IV therapy, implantation, stem cell therapy, oncology therapy, blood transfusion and/or organ transplantation. 60

BRIEF DESCRIPTION OF THE DRAWINGS

Several preferred embodiments of the present invention will now be described, by way of example only, with 65 reference to the appended drawings in which:

FIG. 1 is a perspective view of a syringe assembly;

4

FIG. 2 is a sectional view of a portion of the assembly of FIG. 1:

FIGS. 3 and 4 are sectional views of the assembly of FIG. 1 in two alternate operative positions;

FIG. 5 is a fragmentary sectional perspective view of a portion of another syringe assembly;

FIGS. 6 and 7 are fragmentary perspective views of another syringe assembly;

FIGS. 8 to 12 are fragmentary sectional views of the syringe assembly of FIG. 6;

FIG. 13 is a fragmentary perspective view of yet another syringe assembly; and

FIGS. 14 and 15 are fragmentary sectional views of the syringe assembly of FIG. 13 or portions thereof.

DESCRIPTION OF THE PREFERRED **EMBODIMENTS**

Referring to the figures, and in particular FIG. 1, there is a valve unit 14. The syringe 12 has a chamber 20 containing a plunger 22 to form a cavity 24. Referring to FIG. 2, the cavity has an outlet 26 and the valve unit 14 is located downstream of the outlet 26 for coupling the cavity 24 with a medical accessory such as a needle 30 (as shown in FIGS. 3 and 4). The valve unit 14 has an outlet 32 and flow control means, as will be described, to control fluid flow through the outlet, the flow control means being operable to open the outlet when the coupling section is operatively connected with the medical accessory, the flow control means being operable to close the outlet when the valve unit is disconnected from the medical accessory and to remain closed until connected once again with a medical accessory.

In this case, the chamber 20 includes a first male luer end portion 34 adjacent the outlet 26 and the valve unit 14 includes a first female luer end portion 36 which is engageable with the male luer end portion 34. The valve unit 14 also includes a second male luer end portion 38 for coupling with the medical accessory 30.

Although the chamber 20 and the valve unit 14 are separate from one another in this case, it will be understood that they may, alternatively, be integrally formed, for example by combining the first male luer end portion 34 with the female luer end portion 36.

The valve unit 14 has a channel 42 for the transfer of fluids between the female and male luer end portions 36, 38. A valve means, in the form of a valve member 44 is located in the valve unit 14 and is movable between a first position (as shown in FIG. 2), in which the channel is closed, and a second position (as shown in FIG. 3), in which the channel is open. An actuating means, in the form of an actuating member 46 (shown in FIG. 2), extends outwardly from the valve member 44 and into the male luer end portion 38. The actuating member 46 is coupled to the valve member 44 to actuate it when a female luer end portion of the medical accessory 30 is engaged with the male luer end portion 38.

In the embodiment of FIGS. 1 to 4, the male luer end portion 38 has an outer threaded sheath 50 which is spaced from an inner projection 52. In this case, the actuating member 46 is positioned between the outer threaded sheath 50 and the inner projection 52. The valve member 44 includes a valve plug portion 54 moveable relative to a valve seat portion 56. The valve member 44 has an upper end which is integrally formed with the female luer end portion 36. An outer housing member 58 is slidably mounted on the valve member 44. In this case, the outer housing member 58 is joined to the male luer end portion 38. The valve member

44 also has a valve channel 44a extending from the female luer end portion 36 to the valve plug portion 42 where it terminates at one or more transverse flow openings 44b to join with the channel 42.

The valve member 44 includes an anchor flange 60, and the male luer end portion 38 seats, directly or indirectly, against the anchor flange 60 when the valve is in the closed position as viewed in FIG. 2. Conversely, the male luer end portion 38 is spaced from said anchor flange when the valve is in the open position as shown in FIG. 3.

The outer housing **58** terminates at a radially inwardly directed end region **62** adjacent the female luer end portion **34** and a biasing means in the form of a compression spring **64** is located within the outer housing between the end ¹⁵ region **62** and the anchor flange **60** to bias the valve member toward the first position to close the valve unit.

An alternative arrangement is shown in FIG. 5. In this case, the valve unit 70 has a housing 72 which is integrally formed with the female luer end portion 74. A first channel 20 portion 76 is adjacent the female luer end portion 74 and a second channel portion 78 is adjacent a male luer end portion 80. In this case, the valve means includes a valve member 82 having a valve channel 84 in fluid communication with the first and second channel portion is formed at 90 in the second channel portion 78.

The valve member 82 includes a plug portion 92 which is movable relative to and within the second channel portion 78 for engaging the seat portion 90 to close the second 30 channel portion 78. The first channel portion 76 includes a tubular projection 94 extending from the female luer end portion 74. In this case, the valve channel 84 in the valve member 82 is coextensive with the first and second channel portions 76, 78. In this case, the tubular projection 94 is 35 slidably engaged with the valve member 82 within the valve channel 84 and sealed therein by way of seal 98. Likewise, the valve member 84 is sealed within the second channel portion 78 by way of seal 100.

The syringe assembly 10 is used as follows. First, the 40 valve unit 14 is joined to the syringe 12 by engaging the corresponding first male luer end portion 34 with the female luer end portion 36. In this condition, the second male luer end portion 38 is unattached with a medical accessory such as the needle 30 and the actuator 46 is fully extended into the 45 second male luer end portion 38 as shown in FIG. 2. Consequently, the valve member 44 is biased to its closed position, thereby engaging the valve plug portion 54 against the valve seat 56.

The needle **30** is then attached to the syringe by engaging 50 the female luer end portion on the needle 30 with the second male luer end portion 38. Doing so causes the female luer end portion on the needle 30 to abut and displace the actuating member 46, thereby causing the valve member 44 to be displaced upwardly (as viewed in FIG. 2) thereby 55 releasing the valve plug portion 54 from its sealed abutment with the valve seat 56 to open the valve channel. The plunger 22 may then be displaced outwardly to cause fluids in the proximity of the pointed end of the needle 30 to be drawn into the cavity 24, by a path starting at the valve seat 56 60 through the channel 42 to the transverse flow openings 44b, to the valve channel 44a and on through the female luer end portion and into the cavity 24. The needle 30 may then be removed causing the actuating member 46 to be displaced downwardly (as viewed in FIG. 2) causing the immediate 65 displacement of the valve plug portion to abut the seat 56 and thereby close the valve.

Another device is shown at **120** FIGS. **6** to **12**, having a body **122** forming an inner chamber **124** therein to contain a fluid material. A valve assembly **126** is in fluid communication with the chamber **124** and has a male coupling member **128** for engaging a female coupling member **130** on a medical accessory (in this case a needle **132**) to form a fluid coupling between the device **120** and the needle **132**.

The valve assembly **126** is operable to control fluid flow through the male coupling member **128** and more particularly to be in an open position when the male coupling member **128** is operatively connected with the female coupling member **130** and, conversely, to be in a closed position when the male coupling member **128** is disconnected from the female coupling member **130**.

In this case, the body 122 and the valve assembly 126 are integrally formed and, as seen in FIG. 8, the latter includes a valve member 134 and a valve seat 136. The valve member 134 is shown in its position against the valve seat 136 to close the male coupling member 128, but for a very minor gap there between for illustrative purposes only.

The male coupling member 128 includes an inner male portion 140 having an inner fluid channel 140*a* and an outer sheath portion 142 spaced from the inner male portion 140 to form a passage 144 there between for receiving the female coupling member 130. At least one, in this case three, valve actuating portions 146 (two being shown in FIG. 7) are positioned in the passage 144 to abut the female coupling member 130 and to displace the valve member during the travel of the female coupling member 130 along the passage 144. In this case, each valve actuating portion 146 is integrally formed with the valve member 134.

Each valve actuating portion 146 includes a pair of abutment elements 150, 152 which are spaced from one another along the passage 144 to receive the female coupling member 130 there between and to travel with the female coupling member along the passage 144. The abutment element 152 has a bevelled outer surface 152a for reasons to be described. Each actuating portion 146 is longitudinally oriented relative to the passage 144 and the abutment elements 150, 152 are positioned along the actuating portion 146.

Each valve actuating portion 146 includes a locking flange 154 and the valve assembly includes a locking seat 156 to receive the locking flange 154 when the valve member 134 is in the closed position. In this case, the valve actuating portion 146 has a distal end region and the locking flange 154 is located in the distal end region, while the locking seat 156 is formed in the outer sheath portion 142.

It will be seen in FIG. **10** that each valve actuating portion **146** is arranged to flex in order to displace the locking flange **154** out of the locking seat **156**.

Referring to FIG. 8, the valve member 134 includes a back plate 160 and the actuating portions 146 are equally spaced on the back plate 160. The back plate 160 has a central fluid channel 162 which is in fluid communication with the chamber 124 and the valve member 134 has a fluid channel 163 therein in fluid communication with the central fluid channel 162 and hence the chamber 124. In addition, the fluid channel 163 has a lateral portion 163*a* which establishes fluid communication between the fluid channel 163 and an inner fluid channel 140*a* in the inner male portion.

The device **120** is thus used as follows. The valve assembly is set with the valve member in its closed position, that is with the valve member **134** in its position against the valve seat **136** as shown in FIG. **8**. The female coupling member **130** on the needle **132** is aligned with the passage

144 and brought toward the male coupling member 128. The bevelled leading surface 152a on the abutment member 152aids to centre the female coupling member on the mouth of the passage 144. With the locking flange 154 in the locking seat 156, the female coupling member 130 is able to pass the lowermost edge of the abutment element 152 and continue into the passage 144 until the female coupling member makes contact with the abutment element 150 as seen in FIG. 9. As seen in FIG. 10, continued inward force on the female coupling member is transferred to the abutment element 150 causing the abutment portion 146 to move inwardly along the passage and thus to draw the locking flange 154 from this locked position in the locking seat 156, causing the abutment portion 146 to flex, until the locking flange 154 is removed from the locking seat 156. At this position, it can be seen that the valve member 134 has moved from the valve seat 136 to open the fluid channel 163 to the needle 132.

Referring to FIG. 11, as the female coupling member 130 ₂₀ is removed from the passage 144, it makes contact with the abutment element 152 and causes the abutment portion 146 to move outwardly along the passage 144 and thus cause the valve member 134 to move toward the valve seat 136. The locking flange 154 approaches, and finally enters, the lock-²⁵ ing seat 156 to coincide with the closure of the valve assembly.

Thus, the device **120** does not make use of a valve member which is biased to its closed position as with the earlier embodiment, but rather relies on the displacement of the female coupling member **130** to draw the valve assembly to its closed position when it is removed from the male coupling member **128**.

Another device is shown at **170** in FIGS. **13** to **15**, having ³⁵ a body **172** providing a chamber **174** therein to contain a fluid material. A valve assembly **176** is in fluid communication with the chamber **174** and has a male coupling member **178** for engaging a female coupling member **180**, again on a needle **181**, to form a fluid coupling between the ⁴⁰ medical dispensing device **170** and the needle **181**.

The valve assembly **176** is operable to control fluid flow through the male coupling member and more particularly to actuate or open the male coupling member **178** when operatively connected with the female coupling member **180** 45 and, conversely, to close the male coupling member **178** when disconnected from the female coupling member **180**.

In this case, the male coupling member **178** includes a projection **182** which is fixed to the body **172**. A sheath portion **184** encircles the projection **182** and is also fixed to 50 the body **172**. The sheath portion **184** and is spaced from the projection **182** to form a passage **186** to receive the female coupling member **180**.

A valve member **190** is movable relative to the projection **182** and forms a fluid channel **192** there between and sealed 55 by an inner seal **193**. The projection **182** includes an inner passage **194** which has one end **194***a* open to the chamber **174** and another end **194***b* which is open to the fluid channel **192**.

Referring to FIGS. 14 and 15, the projection includes an 60 enlarged end portion 198 and the valve member 190 has an outer portion 200 arranged to engage the enlarged end portion 198 to close the fluid channel 192. In this case, the passage 186 ends at an inner wall 202 and the valve member 190 is movable relative to the inner wall 202 under the 65 action of a spring 203 which is positioned in the passage 186 between the valve member 190 and the inner wall 202 to

8

bias the outer end portion 200 of the valve member 190 toward an engaged position with the enlarged end portion 198.

As can be seen in FIG. **15**, the enlarged end portion **198** and the outer end portion **200** on the valve member **190** have mating bevelled surfaces **198***a* and **200***a* respectively.

The valve member **190** is operable to engage the female coupling member **180** and to travel with the female coupling member **180** along the passage **186**. In this case, the female coupling member **180** has a leading segment **180***a* and the outer end portion **200** of the valve member **190** is dimensioned to fit within the leading segment **180***a*.

In contrast to the device 120 of FIG. 6, the device 170 has a valve member 190 which is biased to the closed position. As the female coupling member 180 passes over the projection 182, the leading segment 180a of the female coupling member 180 rides over the outer end portion 200 of the valve element 190. Continued inward displacement of the female coupling member 180 into the passage 186 thus causes the valve member to move relative to the projection 182 until the mating bevelled surfaces 198a, 202a separate to open the fluid channel 192 to the needle. The fluid coupling is thus fully operational when the female and male coupling members are tightly engaged. When the female coupling member 180 is removed from the male coupling member 178, the valve member 190 is returned to its closed position against the projection 198 under the biasing action of the spring 203, to close the male coupling member.

While the present invention has been described for what are presently considered the preferred embodiments, the invention is not so limited. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. The scope of the following claims is to be accorded the broadest interpretation so as to encompass all such modifications and equivalent structures and functions.

The valve unit may be used with other medical fluid delivery devices, such as IV lines, catheters, infusion pumps and the like. The valve unit may also be used on syringes and other medical devices which do not employ the ubiquitous luer coupling arrangement.

The following is claimed:

1. A medical connector comprising:

a housing comprising:

- a proximal region comprising:
 - a female luer end portion including an external thread on an outer surface of the female luer end portion, the female luer end portion being configured to receive a male luer,
 - a first channel portion, and
 - a generally tubular projection extending distally from the female luer end portion, and
- a distal region comprising:
 - a second channel portion, and
 - a shroud comprising an internal thread configured to receive a separate medical connector;
- a fluid flow path extending through the first channel portion and the second channel portion, at least a portion of the fluid flow path being configured to be opened and closed to permit passage of fluid through the medical connector;
- a valve member having a closed position configured to inhibit fluid flow to or from the separate medical connector, the valve member having an open position configured to allow fluid flow to or from the separate medical connector, the valve member being configured to move generally longitudinally along the generally

tubular projection as the valve member transitions between the closed position and the open position, the valve member comprising:

- a valve channel in fluid communication with the first channel portion and the second channel portion, the ⁵ valve channel extending between the valve member and the generally tubular projection, and
- a seal contacting the generally tubular projection, the seal extending generally around at least a portion of the generally tubular projection in both the open position and the closed position,
- wherein a portion of the fluid flow path located within the second channel portion is configured to be selectively opened when the separate medical connector is received by the shroud,
- wherein the seal is positioned closer to the female luer end portion when the valve member is in the open position than when the valve member is in the closed position,
- wherein, when the valve member transitions from the open position to the closed position, an increased fluid volume is created within the valve channel, and wherein the valve member is biased towards the closed position; and 25
- an actuating member positioned between the second channel portion and the shroud of the distal region of the housing, the actuating member configured to actuate the valve member from the closed position to the open position, wherein the actuating member is in contact with the valve member at a location proximal from a distal end of the valve member.

2. The medical connector of claim **1**, wherein the generally tubular projection is located entirely within the proximal region of the housing.

3. The medical connector of claim **1** wherein the generally tubular projection comprises a distal end tip located proximal from the shroud.

4. The medical connector of claim **1** wherein a portion of $_{40}$ the fluid flow path located within the valve channel increases in width when the valve member transitions from the open position to the closed position.

5. The medical connector of claim **1** wherein the fluid flow path comprises proximal fluid path region located within the ⁴⁵ first channel portion and a distal fluid path region located within the second channel portion, and wherein the distal fluid path region and the proximal fluid path region are separated by an internal wall when the valve member is in the open position.

6. The medical connector of claim **1**, wherein the fluid flow path comprises a longitudinal section and a transverse section, and wherein the longitudinal section is in fluid communication with the transverse section.

7. The medical connector of claim 6, wherein the transverse section is positioned within the distal region of the housing.

8. The medical connector of claim **1**, wherein the valve member comprises a plug at the distal end of the valve $_{60}$ member, the plug configured to selectively obstruct fluid flow to or from the separate medical connector.

9. The medical connector of claim **1**, wherein the valve member is formed of a single piece of material.

10. The medical connector of claim **1**, wherein at least a 65 portion of the actuating member extends along the shroud when the valve member is in the closed position.

10

11. The medical connector of claim 1 further comprising a second seal located distal from the seal of the valve member, the second seal configured to maintain fluid within the fluid flow path.

12. The medical connector of claim **11**, wherein the second seal does not move along with the valve member.

13. The medical connector of claim **1** further comprising a biasing member configured to bias the valve member toward the closed position.

14. The medical connector of claim 13, wherein the biasing member is located within the proximal region of the housing.

15. The medical connector of claim 1, further comprising:

- a second seal located distal from the seal of the valve member, the second seal configured to maintain fluid within the fluid flow path; and
- a biasing member configured to bias the valve member toward the closed position,
- wherein a portion of the fluid flow path located within the valve channel increases in width when the valve member transitions from the open position to the closed position,
- wherein the fluid flow path comprises a longitudinal section and a transverse section, and wherein the longitudinal section is in fluid communication with the transverse section, and
- wherein at least a portion of the actuating member extends along the shroud when the valve member is in the closed position.

16. A medical connector comprising:

a housing comprising:

- a proximal region comprising a female luer end portion and a generally tubular projection extending from the female luer end portion, the proximal region comprising a first channel portion, and
- a distal region comprising a shroud, the shroud comprising an internal thread configured to receive a separate medical connector, the distal region comprising a second channel portion;
- a valve member having a closed position and an open position, the valve member being configured to move generally longitudinally between the closed position and the open position with the separate medical connector, the valve member comprising a valve channel portion in fluid communication with the first channel portion and the second channel portion, wherein the valve member is configured to slidably engage the generally tubular projection;
- a seal contacting the generally tubular projection of the proximal region of the housing, the seal extending generally around a portion of the generally tubular projection in both the open position and the closed position;
- a fluid flow path extending through the first channel portion and the second channel portion, the fluid flow path comprising:
 - an intermediate fluid path region being located within the valve channel portion, the intermediate fluid path region comprising an internal fluid volume located between the valve member and the generally tubular projection of the proximal region of the housing,
 - wherein the internal fluid volume of the intermediate fluid path region is smaller when the valve member is in the open position than when the valve member is in the closed position, and

- wherein, when the valve member transitions from the open position to the closed position, the internal fluid volume of the intermediate fluid path region increases, and
- an actuating member configured to actuate the valve member from the closed position to the open position, wherein the actuating member is coupled to the valve member at a location proximal from a distal end of the valve member.

17. The medical connector of claim 16, wherein the generally tubular projection is located entirely within the proximal region of the housing.

18. The medical connector of claim **16**, wherein the generally tubular projection comprises a distal end tip located proximal from the shroud.

19. The medical connector of claim 16, wherein the intermediate fluid path region increases in width when the valve member transitions from the open position to the closed position.

20. The medical connector of claim **16**, wherein the fluid ²⁰ flow path comprises a longitudinal section and a transverse section, and wherein the longitudinal section is in fluid communication with the transverse section.

21. The medical connector of claim **20**, wherein the transverse section is between a distal fluid path region and ²⁵ a proximal fluid path region.

22. The medical connector of claim **16**, wherein the valve member comprises a plug at the distal end of the valve member, the plug configured to selectively obstruct fluid flow to or from the separate medical connector. 30

23. The medical connector of claim **16**, wherein the valve member is formed of a single piece of material.

24. The medical connector of claim **16**, wherein at least a portion of the actuating member extends along the shroud when the valve member is in the closed position.

25. The medical connector of claim **16** further comprising a second seal located distal from the seal, the second seal configured to maintain fluid within the fluid flow path.

26. The medical connector of claim **25**, wherein the second seal does not move along with the valve member.

27. The medical connector of claim **16** further comprising a biasing member configured to bias the valve member toward the closed position.

28. The medical connector of claim **27**, wherein the biasing member is located within the proximal region of the housing.

- **29**. The medical connector of claim **16**, further comprising:
 - a second seal located distal from the seal, the second seal configured to maintain fluid within the fluid flow path; and
- a biasing member configured to bias the valve member toward the closed position,
- wherein the intermediate fluid path region increases in width when the valve member transitions from the open position to the closed position,
- wherein the fluid flow path comprises a longitudinal section and a transverse section, and wherein the longitudinal section is in fluid communication with the transverse section, and
- wherein at least a portion of the actuating member extends along the shroud when the valve member is in the closed position.

* * * * *